Location History:
- New York, NY (US) (2013)
- Roslyn, NY (US) (2013 - 2015)
Company Filing History:
Years Active: 2013-2015
Title: Innovations by Glenn L Stoller in Ocular Disease Treatment
Introduction
Glenn L Stoller is a notable inventor based in Roslyn, NY, who has made significant contributions to the field of ocular disease treatment. With a total of three patents to his name, Stoller's work focuses on innovative methods and compositions aimed at addressing various ocular conditions.
Latest Patents
Stoller's latest patents include groundbreaking inventions such as the "Anti-S1P antibody treatment of patients with ocular disease." This invention involves the administration of an anti-S1P antibody or its derivatives to patients suffering from ocular diseases, particularly those involving choroidal neovascularization. The methods aim to reduce the size of lesions in the eye, improve visual acuity, and provide effective treatment for age-related macular degeneration. Another significant patent is related to "Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions." This invention utilizes immune-derived moieties that target the bioactive lipid sphingosine-1-phosphate, aiming to prevent and treat ocular diseases characterized by inflammation and aberrant neovascularization.
Career Highlights
Stoller is associated with Lpath, Inc., a company dedicated to developing innovative therapies for various diseases. His work has been instrumental in advancing treatment options for patients with ocular conditions, showcasing his commitment to improving healthcare outcomes.
Collaborations
Throughout his career, Stoller has collaborated with notable professionals in the field, including Roger A Sabbadini and William A Garland. These collaborations have contributed to the development of his innovative patents and have enhanced the impact of his work in ocular disease treatment.
Conclusion
Glenn L Stoller's contributions to ocular disease treatment through his innovative patents highlight his dedication to advancing medical science. His work continues to pave the way for new therapeutic options, ultimately benefiting patients suffering from ocular conditions.